Company Overview
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +65.42% |
| 6 Months: | -59.93% |
| 3 Months: | -43.81% |
| 1 Month: | -34.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KAPA Kairos Pharma, Ltd. PHARMA | 1.77 | -0.90 | $5.99M | 0.00% | -87.87% | -113.96% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -287.00K | -287.00K | -222.00K | -383.00K | -1.27M | -1.46M | -1.44M | -1.69M |
| Net Income | -312.00K | -323.00K | -253.00K | -1.05M | -1.26M | -1.42M | -1.40M | -1.65M |
| Diluted EPS | -0.03 | -0.03 | -0.02 | -0.10 | -0.08 | -0.08 | -0.07 | -0.08 |
| R&D Expense | 33.00K | 165.00K | 63.00K | 14.00K | 493.00K | 496.00K | 608.00K | 684.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -1.71M | -2.34M | -5.57M |
| Net Income | -1.81M | -2.60M | -5.45M |
| Diluted EPS | -0.17 | -0.23 | -0.30 |
| R&D Expense | 82.00K | 414.00K | 2.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.04M | 965.00K | 5.77M | 6.54M |
| Current Assets | - | 437.00K | 101.00K | 4.17M | 5.39M |
| Cash & Equivalents | - | 437.00K | 93.00K | 1.27M | 4.49M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 2.21M | 3.04M | 992.00K | 199.00K |
| Current Liabilities | - | 1.63M | 2.40M | 992.00K | 199.00K |
| Long Term Debt | - | 582.00K | 638.00K | - | - |
| Total Debt | 380.00K | 582.00K | 638.00K | - | - |
| Total Equity | - | -1.18M | -2.08M | 4.78M | 6.34M |
| Shares Outstanding | - | 12.84M | 12.84M | 13.74M | 20.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 81.00K | -3.96M | -3.44M |
| Financing Cash Flow | -425.00K | 5.13M | 6.66M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 87.2% | -54.5% | -85.9% |
| ROCE % | 119.0% | -49.1% | -87.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 0.19% | 44.26K | $76.57K |
| 2 | Vanguard Capital Management LLC | 0.14% | 33.12K | $57.31K |
| 3 | Virtu Financial LLC | 0.05% | 11.73K | $20.29K |
| 4 | Geode Capital Management, LLC | 0.05% | 11.28K | $19.50K |
| 5 | Vanguard Fiduciary Trust Co | 0.04% | 9.13K | $15.79K |
| 6 | Aptus Capital Advisors, LLC | 0.03% | 6.33K | $10.95K |
| 7 | SevenBridge Financial Group, LLC | 0.03% | 6.33K | $10.95K |
| 8 | Jane Street Group, LLC | 0.02% | 4.82K | $8.34K |
| 9 | Susquehanna International Group, LLP | 0.02% | 4.18K | $7.24K |
| 10 | State Street Corporation | 0.01% | 3.44K | $5.96K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KAPA
Kairos Pharma Announces 1-for-7 Reverse Stock Split
LOS ANGELES, August 21, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding …
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
LOS ANGELES, July 22, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s…
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.Founded in 2012, CEO.CA, a whol…
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, C…
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Bayer’s share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on several measures. This raises the question of how much of the recent optimism is already reflected in the price…
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership focuses on combination treatments for me…
KAPA — Frequently Asked Questions
What is the current share price of Kairos Pharma, Ltd. (KAPA)?
As of 2026-09-19 21:16 PDT, Kairos Pharma, Ltd. (KAPA) trades at $1.77 on NYSE American. Its 52-week range is $1.07 to $13.79.
What is the market capitalisation of KAPA?
Kairos Pharma, Ltd. (KAPA) has a market capitalisation of $5.99M on NYSE American.
What is the P/E ratio of KAPA?
KAPA trades at a trailing price-to-earnings (P/E) ratio of -0.90. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.26.
What is the return on equity (ROE) of KAPA?
KAPA has a return on equity (ROE) of -113.96%. Its return on capital employed (ROCE) is -87.87%.
Is KAPA a good stock to buy?
This page provides a data-driven analysis of Kairos Pharma, Ltd. (KAPA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.